Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Granules now has a total of 67 ANDA approvals from the USFDA
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
The recent inspection covered both cGMP and PAI processes
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Subscribe To Our Newsletter & Stay Updated